Core Insights - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune diseases [1] - The company will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with a webcast available for 90 days post-event [1] Company Overview - Q32 Bio targets potent regulators of the adaptive immune system to develop innovative therapies for alopecia areata and other autoimmune and inflammatory diseases [1] - Approximately 700,000 individuals in the U.S. are affected by alopecia areata, which significantly impacts their lives and has limited treatment options [1] Product Development - Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7R antibody, currently in a Phase 2 program for treating alopecia areata [1] - The IL-7 and TSLP pathways are implicated in various T cell-mediated autoimmune diseases, highlighting the potential of Q32 Bio's therapeutic approach [1]

Core Viewpoint - Pasithea Therapeutics Corp. is advancing its lead drug candidate, PAS-004, a next-generation macrocyclic oral MEK inhibitor, aimed at treating NF1-associated plexiform neurofibromas and is actively participating in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [1][2]. Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on the research and development of PAS-004, which targets RASopathies, MAPK pathway-driven tumors, and other diseases [4]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial for adult patients with NF1-associated plexiform neurofibromas (NCT06961565) [4]. Event Details - The presentation by CEO Tiago Reis Marques is scheduled for February 26, 2026, from 4:00 to 4:30 PM ET, and will be available for viewing via a live webcast [2][3]. - Management will also be available for one-on-one meetings with qualified investors registered for the conference [2].

Core Insights - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to address resistance to cancer immunotherapy [1] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 pm ET [1] Company Overview - TuHURA is developing technologies to overcome primary and acquired resistance to cancer immunotherapy, which are common reasons for the failure of these treatments [1] - The lead product, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors and is currently in a Phase 3 registration trial as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel Cell Carcinoma [1] Recent Developments - TuHURA acquired TBS-2025 through its merger with Kineta Inc. on June 30, 2025; TBS-2025 is a VISTA inhibiting monoclonal antibody moving into Phase 2 development for mutNPM1 r/r AML [1] - The company is also leveraging Delta Opioid Receptor technology to develop first-in-class bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells [1]

Upgrades - Raymond James upgraded Take-Two (TTWO) to Strong Buy from Outperform with an unchanged price target of $285, viewing the recent selloff as overdone and presenting a more attractive risk/reward scenario for the company [2] - Daiwa upgraded Palantir (PLTR) to Buy from Neutral with a price target of $180, down from $200, citing a positive impression from the earnings release [2] - Gordon Haskett upgraded Booking Holdings (BKNG) to Buy from Hold with a price target of $5,440, believing that investors have overreacted to AI-driven competitive concerns and have discounted Booking's operational advantages [3] - Oppenheimer upgraded Unity (U) to Outperform from Perform with a price target of $38, arguing that fears regarding competition from "world models" like Google's Project Genie are misplaced and overlook Unity's unique role in development [4] - Arete upgraded Snap (SNAP) to Buy from Neutral with a price target of $7.30, noting a shift in the company's sales growth from a "sub-scale" advertising business to higher margin, recurring subscription income [5] Downgrades - HSBC downgraded Estee Lauder (EL) to Hold from Buy with a price target of $106, stating that Estee's "modest" organic sales upgrade in the quarter underwhelmed investors relative to expectations [6] - Citi downgraded Under Armour (UAA) to Sell from Neutral with an unchanged price target of $6.20, indicating that the company's turnaround in North America is facing "several pressures" in fiscal 2026 [6] - Raymond James downgraded Wingstop (WING) to Outperform from Strong Buy with an unchanged price target of $325, expressing caution regarding Wingstop's near-term sales trends [6] - Truist downgraded Texas Roadhouse (TXRH) to Hold from Buy with a price target of $188, down from $206, believing that beef price inflation will persist at least through 2027, limiting multiple expansion and pressuring margins and earnings estimates [6] - Loop Capital downgraded Monday.com (MNDY) to Hold from Buy with a price target of $80, down from $195, citing a "fine, but not great" quarter amid moderating upmarket momentum and slower adoption of newer products [6] - Baird also downgraded Monday.com to Neutral from Outperform with a price target of $90, down from $175 [6]

Core Viewpoint - Reddit reported strong fourth quarter earnings, exceeding expectations in user and ad growth, but experienced a mixed market reaction with its stock price fluctuating post-earnings announcement [1][2][3]. Financial Performance - Reddit's earnings per share (EPS) was $1.24, surpassing the expected $0.94 [3]. - Revenue reached $726 million, a 70% increase year-over-year, also beating expectations [4]. - For the first quarter of 2026, Reddit projected sales between $595 million and $605 million, higher than market expectations, with earnings projected between $210 million and $220 million, exceeding the estimate of $203 million [4]. Analyst Ratings and Price Targets - Guggenheim raised its price target for Reddit from $245 to $255, maintaining a buy rating, citing strong revenue and profit growth [6]. - Several analysts lowered their price targets, but all remain significantly above the current trading price of $145. For instance, Evercore ISI reduced its target from $320 to $290, while Oppenheimer lowered it from $300 to $250 [7][9]. - Caner Fitzgerald lowered its price target to $170 from $240, maintaining a neutral rating, indicating strong growth but cautioning on user growth trajectory [10][11]. Market Reaction - Despite the strong earnings report, Reddit's stock initially rose but then fell by 4%, indicating a mixed market sentiment [1][2]. - Analysts noted that the downward movement in stock price may be influenced by sector-wide deratings, with many firms adjusting their targets due to broader market conditions [8][12].

Core Insights - Nutrien Ltd. (NYSE:NTR) is considered one of the most undervalued Canadian stocks by hedge funds, with recent price target adjustments indicating a positive outlook despite market caution [1][2]. Group 1: Price Target Adjustments - Scotiabank raised its price target for Nutrien to $70 from $63 while maintaining a Sector Perform rating, advising caution regarding fertilizer markets after the spring season [1]. - Oppenheimer increased its price target for Nutrien to $76 from $64, keeping an Outperform rating, and expects stock performance to be driven by specific company catalysts despite challenges in the broader agriculture sector [2]. Group 2: Industry Themes and Company Segments - Key industry themes identified by Oppenheimer include consolidation, affordability, and innovation, with input demand influenced by customer value perception [3]. - Nutrien operates through four segments: Nutrien Ag Solutions, Potash, Nitrogen, and Phosphate, providing crop inputs and services [3].

Group 1 - Oppenheimer Holdings (OPY) reported a strong quarter, benefiting from relatively fixed costs and operating leverage across its segments [2] - Wealth management performed well due to higher Assets Under Management (AUM) and increased market valuations [2] - The Valkyrie Trading Society is a team of analysts focused on high conviction, obscure developed market ideas that are expected to yield non-correlated and outsized returns in the current economic environment [2] Group 2 - The Value Lab is an investment group that targets long-only value ideas, aiming for a portfolio yield of approximately 4% [1] - The Value Lab provides members with real-time updates, 24/7 chat support, regular global market news reports, feedback on stock ideas, monthly new trades, quarterly earnings write-ups, and daily macro opinions [2]

Group 1 - Via Transportation, Inc. (NYSE:VIA) is identified as one of the 12 tech stocks with significant upside potential, with Oppenheimer analyst Brian Schwartz lowering the price target from $59 to $40 while maintaining a Buy rating [1] - Oppenheimer views Via as a company with strong fundamentals and a compelling long-term growth profile, expecting it to be one of the fastest-growing software companies in terms of revenue by 2026 [2] - Morgan Stanley's Josh Baer also reduced the price target from $53 to $41 but upgraded the stock from Hold to Buy, indicating a potential upside of 74.47% from current levels [3] Group 2 - Via Transportation, Inc. provides a digital public transportation platform globally, operating and developing TransitTech, a public mobility platform, founded in 2012 and based in New York [4]

Core Insights - Waste Management, Inc. (WM) is a leading provider of waste management services in North America, offering collection, transfer, recycling, and disposal services [1] - Oppenheimer has set a price target of $264 for WM, indicating a potential price increase of 18.32% from its current price of $223.13 [1][5] - AlphaQuest LLC has increased its investment in WM by 131.8%, reflecting strong confidence in the company's future performance [2][5] Market Performance - WM's current stock price is $223.13, which represents a decrease of 3.66% or $8.47, with fluctuations during the trading day ranging from a low of $220.84 to a high of $231.67 [3] - Over the past year, WM's stock has reached a high of $242.58 and a low of $194.11, indicating volatility in the stock market [3] - WM's market capitalization is approximately $89.89 billion, showcasing its significant presence in the waste management industry [4][5] Investor Interest - The trading volume on the NYSE for WM is 3,670,753 shares, indicating active investor interest [4] - Other investment firms, such as Cornercap Investment Counsel Inc. and Wealthfront Advisers LLC, have also adjusted their positions in WM, reflecting broader interest in the company's potential [2]

Financial Performance - Oppenheimer Holdings Inc. reported a net income of $74.4 million for Q4 2025, a 593.1% increase from $10.7 million in Q4 2024, with revenue rising 25.9% to $472.6 million[1][2]. - For the full year 2025, net income reached $148.4 million, up 107.4% from $71.6 million in 2024, while revenue increased 14.4% to $1.6 billion[2]. - Total revenue for FY-25 was $591.3 million, a 32.0% increase from $447.6 million in FY-24[30]. - Pre-tax income for FY-25 was $56.2 million, compared to a loss of $39.6 million in FY-24[30]. - The effective tax rate improved to 29.9% in FY-25 from 32.6% in FY-24[37]. Segment Performance - Wealth Management segment revenue for Q4 2025 was $287.3 million, a 13.3% increase year-over-year, with pre-tax income rising 84.0% to $98.8 million[12][21]. - Capital Markets segment revenue for Q4 2025 was $182.9 million, a 53.3% increase compared to Q4 2024, with pre-tax income of $52.8 million compared to a loss of $5.0 million a year ago[16][19]. - The Capital Markets segment saw a significant increase in investment banking activity, with advisory fees from investment banking up 41.3% year-over-year[19]. - Investment banking revenue increased by 56.0% to $260.4 million from $166.8 million in the prior year[30]. - Equities underwriting fees surged by 163.8% compared to the prior year, reflecting higher new issuance activity in key sectors[32]. - Fixed income underwriting fees increased by $7.1 million, or 60.0%, due to a higher number of public finance transactions[32]. Expenses and Dividends - Compensation expenses increased to $260.1 million in Q4 2025, up from $256.4 million in Q4 2024, primarily due to higher production-related expenses[3][7]. - Non-compensation expenses for the full year 2025 rose to $410.4 million, reflecting higher underwriting and technology-related costs[3][7]. - Total expenses for FY-25 were $535.1 million, up 9.8% from $487.2 million in FY-24[30]. - The company declared a special dividend of $1.00 per share, payable in January 2026, and repurchased 46,292 shares at an average price of $64.36 during the year[7][9]. - The company announced a quarterly dividend of $0.18 per share for Q4 2025, payable on February 27, 2026[37]. Market Position and Outlook - Assets Under Management (AUM) reached a record $55.2 billion as of December 31, 2025, reflecting a $5.8 billion increase from the previous year due to market appreciation[15][21]. - The company remains well-positioned to navigate evolving market conditions and capitalize on opportunities across its businesses as it enters 2026[9]. - Retail commissions increased by 6.2% year-over-year, reaching a record high due to higher retail transaction volumes[26]. - Advisory fees rose by 14.9% from the prior year, driven by higher billable AUM and increased incentive fees from alternative investments[26].